Radius Health announced B-FLEXION Life Sciences has agreed to acquire the remaining 57% interest in the specialty biopharmaceutical company, purchasing shares currently held by affiliates of Patient Square Capital and Webster Equity Partners.
The deal will consolidate Radius’s ownership under B-FLEXION, following the company’s August 2022 take-private transaction led by B-FLEXION and Patient Square. Radius said the transaction is expected to close by the end of the first quarter of 2026, subject to customary closing conditions.
Radius, which focuses on bone health and related therapeutic areas, said it has sharpened its commercialization strategy over the past three years while delivering sustained growth under B-FLEXION and Patient Square’s ownership. The company’s lead product is TYMLOS (abaloparatide) injection, an osteoporosis treatment approved by the U.S. Food and Drug Administration for postmenopausal women and men at high risk for fracture, as well as for patients who have failed or are intolerant to other available osteoporosis therapies.
Scott Briggs, CEO of Radius Health, said the business has undergone a transformation since the 2022 take-private, emphasizing commercial execution and expanded patient reach for TYMLOS. B-FLEXION Life Sciences Operating Partner Nithya Desikan said Radius has become a “strong, profitable business” within the firm’s portfolio and pointed to continued investment in commercial capabilities to support the product’s growth.
Patient Square Managing Partner Jim Momtazee said the firm’s initial investment thesis has played out as expected and characterized the timing as an opportunity to deliver returns to investors while enabling the company’s next phase under a consolidated ownership structure.
The financial terms were not disclosed.
Support: Centerview Partners served as financial advisor to Radius.
KEY QUOTES:
“Over the past three years, Radius has undergone a significant transformation, sharpening our focus on commercialization and delivering sustained growth. We are grateful for the support our partners have provided, which has enabled us to deliver TYMLOS® to an increasing number of patients living with osteoporosis.”
Scott Briggs, Chief Executive Officer, Radius Health
“We are extremely proud of the momentum of what has become a strong, profitable business within our portfolio. The team has built incredible commercial capabilities, and we look forward to continuing the success of TYMLOS® as it provides meaningful impact to the patients and families we serve.”
Nithya Desikan, Operating Partner, B-FLEXION Life Sciences; Board Member, Radius
“We are proud of the transformation achieved at Radius over the past three years by Scott and his team expanding the impact of an important medicine. With our initial investment thesis playing out as expected and with a bright future ahead, it is a good time to deliver returns for our investors and consolidate ownership of the Company for its next stage of growth.”
Jim Momtazee, Managing Partner, Patient Square Capital
